The Group has chosen to concentrate its efforts on several major priorities. Diabetes, oncology, ophthalmology, infectious diseases, elderly patients and ageing, immuno-inflammation, fibrosis and tissue repair are strategic therapeutic areas.

Other high priority areas for the Group, where it benefits from considerable experience, include neurodegenerative diseases, psychiatry, epilepsy and cardiovascular diseases/thrombosis.

Genzyme's areas of research and development can be found on its website:

With 250 million people worldwide affected by diabetes, this disease constitutes a major public health challenge. Sanofi's aim is to offer all-round therapeutic solutions to patients – medicines, medical devices, services, etc. Among other areas, our research concerns the development of drugs with a sustained action or supplied in a combination, the correction of metabolic disorders and their cardiovascular consequences, and the range of different pathological conditions induced by diabetes (nephropathy, neuropathy, retinopathy, etc).

Sanofi is a leader in oncology, and notably in chemotherapy. Its aim is to combat cancer in all its different forms by carrying out research on the different pathways involved in the development, growth and propagation of cancer cells.
The oncology R&D portfolio contains a range of innovative agents with different mechanisms of action. Several major partnerships concluded in 2010 and focused on novel therapeutic approaches have further enhanced Group presence in this field.

Understanding and managing aging-related pathologies and disorders, a field where many medical needs are as yet unmet, are crucial areas for R&D at Sanofi. Pain, quality of life, independence, the adaptation of pharmaceutical formulations for the elderly or the design of innovative and integrated health solutions are important areas for development in this field.

The Ophthalmology Division develops innovative compounds for the treatment of eye diseases, including age-related macular degeneration (ARMD), retinal degeneration, macular oedema, glaucoma and Stargardt's disease.

The Immuno-Inflammation teams are centered on discovering and developing innovative healthcare solutions to major immune-mediated diseases such as inflammatory bowel disease, multiple sclerosis, psoriasis and selected atopic diseases.
Our strategy is based on early clinical credentialing of mechanistic pathways and applied translational medicine.

By studying the mechanisms that trigger the development of tissue fibrosis, Sanofi strives to produce innovative new agents to treat and/or prevent fibrosis and preserve organ function. Potential indications include pulmonary fibrosis, primary biliary cirrhosis, liver fibrosis, healing phenomena and wound repair.

In the field of prevention, Sanofi Pasteur is exploring novel technologies and the most recent scientific findings in order to develop safe and effective vaccines with a single or combined target against complex diseases that affect populations throughout the world, such as dengue fever and infections caused by C. difficile.
At the same time, our research efforts are focusing on the treatment of multi-resistant hospital-acquired infections, malaria and other parasitic diseases thanks to new antibiotics, antivirals, anti-infective agents and agents that stimulate resistance to infections.